Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T13491
|
||||
Former ID |
TTDS00430
|
||||
Target Name |
Equilibrative nucleoside transporter 1
|
||||
Gene Name |
SLC29A1
|
||||
Synonyms |
ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; Nucleoside transporter 1; Nucleoside transporter, es-type; Solute carrier family 29 member 1; SLC29A1
|
||||
Target Type |
Successful
|
||||
Disease | Angina pectoris [ICD9: 413; ICD10: I20] | ||||
Function |
Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (nbmpr) and is sodium-independent.
|
||||
BioChemical Class |
Transmembrane protein
|
||||
Target Validation |
T13491
|
||||
UniProt ID | |||||
Sequence |
MTTSHQPQDRYKAVWLIFFMLGLGTLLPWNFFMTATQYFTNRLDMSQNVSLVTAELSKDA
QASAAPAAPLPERNSLSAIFNNVMTLCAMLPLLLFTYLNSFLHQRIPQSVRILGSLVAIL LVFLITAILVKVQLDALPFFVITMIKIVLINSFGAILQGSLFGLAGLLPASYTAPIMSGQ GLAGFFASVAMICAIASGSELSESAFGYFITACAVIILTIICYLGLPRLEFYRYYQQLKL EGPGEQETKLDLISKGEEPRAGKEESGVSVSNSQPTNESHSIKAILKNISVLAFSVCFIF TITIGMFPAVTVEVKSSIAGSSTWERYFIPVSCFLTFNIFDWLGRSLTAVFMWPGKDSRW LPSLVLARLVFVPLLLLCNIKPRRYLTVVFEHDAWFIFFMAAFAFSNGYLASLCMCFGPK KVKPAEAETAGAIMAFFLCLGLALGAVFSFLFRAIV |
||||
Drugs and Mode of Action | |||||
Inhibitor | 6-(4-Nitro-benzylsulfanyl)-9-phenethyl-9H-purine | Drug Info | [527247] | ||
9-Benzyl-6-(4-nitro-benzylsulfanyl)-9H-purine | Drug Info | [527247] | |||
Dilazep | Drug Info | [536024] | |||
KF24345 | Drug Info | [526889] | |||
LIDOFLAZINE | Drug Info | [528952] | |||
N6-CYCLOPENTYLADENOSINE | Drug Info | [527371] | |||
NBTGR | Drug Info | [543366] | |||
Nitrobenzylthioinosine | Drug Info | [536793] | |||
S6-nitrobenzyl mercaptopurine riboside | Drug Info | [529877] | |||
Modulator | [3H]nitrobenzylmercaptopurine ribonucleoside | Drug Info | [543366] | ||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
DRM | DRM Info | ||||
References | |||||
Ref 526889 | Interaction of the novel adenosine uptake inhibitor 3-[1-(6,7-diethoxy-2-morpholinoquinazolin-4-yl)piperidin-4-yl]-1,6-dimethyl-2,4(1H,3H)-quinazolinedione hydrochloride (KF24345) with the es and ei subtypes of equilibrative nucleoside transporters. J Pharmacol Exp Ther. 2004 Mar;308(3):1083-93. Epub 2003 Nov 21. | ||||
Ref 527247 | J Med Chem. 2004 Oct 21;47(22):5441-50.Inhibition of nucleoside transport by new analogues of 4-nitrobenzylthioinosine: replacement of the ribose moiety by substituted benzyl groups. | ||||
Ref 527371 | J Med Chem. 2005 Jan 13;48(1):321-9.Inhibition of nucleoside transport proteins by C8-alkylamine-substituted purines. | ||||
Ref 528952 | J Med Chem. 2007 Aug 9;50(16):3906-20. Epub 2007 Jul 18.Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. | ||||
Ref 529877 | Bioorg Med Chem Lett. 2009 Feb 1;19(3):917-21. Epub 2008 Dec 6.Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. | ||||
Ref 536024 | Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-mercaptopurine riboside, and dipyridamole. Mol Pharmacol. 2005 Mar;67(3):837-44. Epub 2004 Nov 19. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.